All In Biotech

Drug Trial Radar · NCT07222878

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Participants With Co-administered Agent

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Sep 29, 2025

Primary completion

Nov 4, 2025

Study completion Nov 4, 2025

Sponsor

Lead sponsor
NeuroPro Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules

Conditions

  • Epilepsy
  • Alzheimer Disease
  • Epilepsy Intractable

Interventions

  • NPT 2042 (Reference formula/Formulation 1)Drug

    In Period 1 Day 1, participants will receive Formulation 1 in a fasted state (Treatment A).

  • NPT 2042 (Test formula/Formulation 2)Drug

    Following a 3-day wash out, in Period 2 Day 1, participants will receive Formulation 2 in a fasted state (Treatment B).

  • NPT 2042 (Test formula/Formulation 2)Drug

    Following a 4-day wash out, in Period 3 Day 1, participants will receive Formulation 2 in a fasted state with co-administered agent (Treatment C).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
  2. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
  3. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
  4. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
  5. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
  6. To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
  7. To calculate the Frel and 90% confidence intervals for Formulation 1 (Reference) vs Formulation 2 (Test) both administered in a fasted state.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1) and Tx. Period 2 (Day 4)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.